[Lipoma of the uterus: clinical and ethiopathological approach of 7 cases with immunohistochemical study of histogenesis]
Case report
OA: closed
CC0
AI-generated summary
This study investigated 7 uterine lipoleiomyoma cases, finding that fatty and smooth muscle cells expressed distinct markers, suggesting a benign tumoral origin from totipotent mesenchymal cells rather than degeneration.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BACKGROUND: Lipoleiomyoma of the uterus (LLU) is an extremely rare, benign, uterine tumour. This rare disease was unknown for a long time. Their histogenesis remains controversial.
AIM: To describe the clinical and pathological aspects of uterine lipoleiomyoma and to try to specify, by an immunohistochemical study, its degenerative or tumoral nature.
METHODS: 7 cases of LLU were identified represented by 2 pure Lipoma and 5 Lipoleiomyoma. We performed an immunohistochemical study including anti-vimentin, anti-smooth muscle actin, anti PS-100, anti-desmin, anti-factor VIII and anti-HMB- 45. The results were correlated with the pathogenesis of this lesion.
RESULTS: Immunohistochemical analysis showed an expression of PS 100 only in lipocytes whereas leiomyomatous cells express only smooth muscle actin.
CONCLUSION: Our study supports the benign tumoral nature of the fatty uterine lesions. Lipoleiomyomatous cells may originate from the transformation of a totipotent mesenchymal cell and not from a degenerative process.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-10-08T21:08:21.741906+00:00
License: CC0
· commercial use OK